Clearside Biomed Stock Price, News & Analysis

Clearside Biomedical, Inc. (NASDAQ:CLSD) will have its Chief Medical Officer, Thomas A. Ciulla, present a company overview and participate as a panelist on August 31, 2022, at the Ophthalmology Futures Retina Forum 2022. Dr. Ciulla will discuss alternatives to intravitreal drug delivery for posterior segment diseases. The forum aims to connect various stakeholders in ophthalmology to foster innovation in eye care. Clearside is known for its revolutionary SCS injection platform, enabling targeted delivery of therapies for sight-threatening diseases.

Clearside Biomedical, Inc. (NASDAQ:CLSD) reported Q2 2022 results with revenues of $384,000, down from $780,000 in Q2 2021. R&D expenses increased to $5.4 million, contributing to a net loss of $7.8 million ($0.13 per share), compared to a net loss of $6.1 million ($0.11 per share) in the prior year. The company completed dosing in two cohorts of the OASIS Phase 1/2a trial for CLS-AX and secured a non-dilutive financing agreement with HealthCare Royalty for up to $65 million to support clinical development. CLS-AX data is expected in November 2022.

Clearside Biomedical has announced a significant Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners on August 8, 2022. The agreement aims to advance the clinical development of its CLS-AX program, which utilizes the suprachoroidal injection platform. Clearside will receive $32.5 million upfront, with an additional $12.5 million in escrow tied to sales milestones for its product, XIPERE. The deal allows Clearside financial flexibility while excluding its internal development programs from the royalty agreement.

Clearside Biomedical (NASDAQ:CLSD) announced participation in three upcoming investor conferences in August 2022. The events include:

• BTIG Biotechnology Conference: Panel Discussion on August 9 at 10:00 am ET in New York City.
• Wedbush PacGrow Healthcare Virtual Conference: Fireside Chat on August 10 at 8:35 am ET.
• H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference: Panel and Corporate Presentation on August 17 at 11:00 am ET.

Links to live and archived webcasts are available on Clearside's website.

Clearside Biomedical (NASDAQ:CLSD) announced it will report its Q2 2022 financial results on August 9, 2022, before market opening. The company specializes in innovative therapies targeting the back of the eye via the suprachoroidal space. A webcast and conference call will be held at 8:30 a.m. ET to discuss the financial results and provide updates on corporate developments. Registration for the event is available on the Clearside website.

Clearside Biomedical has completed dosing in Cohorts 3 and 4 of its Phase 1/2a clinical trial, OASIS, for CLS-AX (axitinib injectable suspension) targeting neovascular age-related macular degeneration (wet AMD). The trial, which enrolled 27 patients, assesses safety and tolerability through suprachoroidal injection. Preliminary data is expected in Q4 2022. CLS-AX, a tyrosine kinase inhibitor, aims to offer better efficacy through broad VEGF blockade. The successful trial completion is seen as a critical milestone for Clearside's innovative drug delivery platform.

Clearside Biomedical (CLSD) announced multiple presentations at the ASRS Annual Meeting and OIS Retina Innovation Summit from July 13-16, 2022, in New York. These presentations will highlight the company’s suprachoroidal delivery platform, XIPERE, and SCS Microinjector technology. Notable discussions include a panel on drug delivery and key presentations on the efficacy of XIPERE for treating macular edema associated with uveitis. XIPERE was FDA-approved in October 2021 and is now commercially available in the U.S.

Clearside Biomedical (NASDAQ:CLSD) has appointed Susan L. Coultas, Ph.D., as its new Chief Clinical Officer. With over 35 years in clinical development, her experience includes senior roles at multiple ophthalmic companies. Dr. Coultas will oversee the planning and execution of Clearside's clinical trials, including the lead candidate, CLS-AX, aimed at treating neovascular age-related macular degeneration. The executive team, including Dr. Thomas Ciulla, will work closely with her to enhance the company’s clinical pipeline and operational effectiveness.

Clearside Biomedical, Inc. (Nasdaq: CLSD) will feature Chief Medical Officer Thomas A. Ciulla in a Fireside Chat at the JMP Securities Life Sciences Conference on June 15, 2022, at 9:30 a.m. ET in New York. This event emphasizes Clearside's innovative SCS injection platform, which enables non-surgical therapy delivery to the eye, targeting conditions that threaten vision. The live and archived webcast will be accessible via the Clearside website for three months. Clearside's first product, XIPERE, is an injectable suspension currently available in the U.S.